THE MOSS REPORTS - CANCER DECISIONS NEWSLETTER

ZETIA FAILS CLINICAL TRIAL…WHY WAS IT EVER APPROVED?

This month, scientists announced the result of the long-awaited ENHANCE
study of the anti-cholesterol drug Zetia (ezetimibe). This drug alone,
or in combination with the popular statin drug, Zocor (simvastatin)
conveyed no medical benefit to patients. In fact, the company-sponsored
study found that the pace at which artery-clogging plaque formed within
blood vessels actually doubled in patients taking the two-drug
combination.

To read or listen to this week's newsletter, please click here or go to:

http://www.cancerdecisions.com/012708.html

[and scroll down]